Abnormal intestinal cells can shed DNA into the digestive tract. A stool sample therefore provides material for examining characteristic mutations and methylation patterns associated with colorectal cancer or precancerous lesions. The approach detects molecular signals carried in the specimen rather than requiring clinicians to inspect the colon directly, which supports a noninvasive screening pathway.
Mutations and methylation patterns provide different types of molecular information about abnormal cells, while occult blood can add a separate signal when included in a test. Considering these findings together broadens the features examined in one stool specimen. This combined design helps screening focus on cellular changes associated with both colorectal cancer and precancerous lesions.
Stool DNA testing looks for molecular evidence carried in a stool sample, whereas structural examinations focus on the physical features of the colon. That distinction makes the stool-based approach noninvasive and suitable as an alternative to some structural screening examinations. It does not mean the methods provide identical information, because an abnormal stool result requires follow-up diagnostic colonoscopy.
After a stool sample is collected, the laboratory examines its genetic material for the specified molecular signs and may also assess occult blood, depending on the test. Clinicians interpret the finding as a screening result rather than a diagnosis. If the result is abnormal, diagnostic colonoscopy is typically used to investigate the colon directly.
Clinicians primarily use this screening approach for eligible adults who do not have symptoms. Its role is preventive: identifying molecular signs associated with colorectal cancer or precancerous lesions before symptoms lead to medical evaluation. In this setting, the test offers a noninvasive option for screening, while an abnormal result initiates the diagnostic pathway rather than confirming disease.
An abnormal result indicates that the stool contains molecular signs that warrant further evaluation; it does not establish colorectal cancer or a precancerous lesion by itself. Diagnostic colonoscopy is typically the next step, allowing clinicians to investigate the finding. Thus, the test functions as an early screening gate, linking molecular detection with definitive diagnostic assessment.